Ovid Therapeutics Inc.
NASDAQ:OVIDBiotechnology
-$0.11 today
- Market cap
- $426.53M
- Beta
- 0.18
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.33
Volume 2.16M
Average 3.07M
OVID Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Ovid Therapeutics Inc.NASDAQ: OVID
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow growth accelerates
Q1 FY2026 free cash flow of $13.9M (cash outflow) rose 35.2% year over year, ahead of the -15.4% change in trailing-twelve-month free cash flow. Sequentially, it rose 33.5% from the prior quarter. Over 3 fiscal years it compounded at -12.2% a year.
Context
- Free cash flow amounted to 528.6% of revenue in FY2025, down 9370.2 pp from a year earlier.
- Free cash flow grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +35.2% holds above the trailing-twelve-month pace of -15.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (38.33M) USD
- Year-over-year change
- +31.6%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (38.33M) | +31.6% |
| FY2024 | 2024-12-31 | (56.03M) | -22.0% |
| FY2023 | 2023-12-31 | (45.92M) | +18.9% |
| FY2022 | 2022-12-31 | (56.65M) | -147.8% |
| FY2021 | 2021-12-31 | 118.42M | — |
Free Cash Flow vs competitors
How OVID compares with its peers on the latest reported figures
- OVID's LTM Mar 2026 free cash flow of $41.95M is the 10th largest of the 11 companies compared; the peer median is $132.76M.
- Its year-over-year change of -15.4% is the 8th highest of 11, against a peer median of +12.7%.
- Free cash flow amounts to 589.1% of revenue for OVID, versus a peer median of 356.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $487.2M | +18.0% | -3.6% | 72.8% | |
| LTM Mar 2026 | $183.34M | +1.1% | +13.2% | 255.4% | |
| LTM Mar 2026 | $179.8M | -15.6% | +0.7% | — | |
| LTM Mar 2026 | $147.7M | -313.4% | — | 460.4% | |
| LTM Jun 2026 | $135.57M | +64.3% | -6.1% | 2471.7% | |
| LTM Mar 2026 | $129.94M | +14.0% | +108.0% | 356.1% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $98.42M | +11.5% | +21.3% | — |
| LTM Mar 2026 | $85.24M | +35.3% | +24.6% | 586.2% | |
| LTM Mar 2026 | $82.61M | +15.9% | +12.5% | — | |
| LTM Mar 2026 | $41.95M | -15.4% | -12.2% | 589.1% | |
| LTM Mar 2026 | $2.34M | -97.9% | -24.8% | 2.9% | |
| Peer median (excluding OVID) | $132.76M | +12.7% | +12.5% | 356.1% | |
Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 119.84M | (54.17M) | (52.34M) | (26.43M) | (17.41M) |
| Depreciation & Amortization | 237K | 1.38M | 1.6M | 613K | 273K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 6.56M | 7.29M | 6.28M | 4.81M |
| Change in Working Capital | (16.81M) | (8.23M) | 2.39M | (150K) | (4.1M) |
| Accounts Receivables | 141.76K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.7M | (5.17M) | 1.75M | (512K) | (1.23M) |
| Other Working Capital | (18.66M) | (3.06M) | 635.51K | 362K | (2.87M) |
| Other Non-Cash Items | 15.35M | (764.94K) | (4.71M) | (36.26M) | (21.9M) |
| Operating Cash Flow | 118.61M | (55.23M) | (45.78M) | (55.96M) | (38.33M) |
| Capital Expenditures | (189.41K) | (1.42M) | (137.46K) | (71K) | 0 |
| Acquisitions (Net) | (1.63M) | (2.5M) | (10M) | 0 | 0 |
| Purchases of Investments | (1.63M) | (172.96M) | (112.44M) | (73.25M) | (91.85M) |
| Sales of Investments | 0 | 90M | 120M | 128M | 42M |
| Other Investing Activities | (5.4K) | (1M) | (97.15K) | (89K) | 0 |
| Investing Cash Flow | (1.82M) | (87.88M) | (2.58M) | 54.59M | (49.85M) |
| Debt Repayment | 0 | 0 | 30M | 0 | 0 |
| Common Stock Issued | 925.4K | 180.66K | 535.2K | 622K | 75.21M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (21.31K) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 904.08K | 180.66K | 30.54M | 622K | 75.21M |
| Effect of Forex Changes | (1.93M) | 0 | 0 | 0 | (167K) |
| Net Change in Cash | 115.76M | (142.93M) | (17.83M) | (740K) | (13.15M) |
| Free Cash Flow | 118.42M | (56.65M) | (45.92M) | (56.03M) | (38.33M) |
Ovid Therapeutics Inc.
NASDAQ:OVID
Intrinsic Alpha fair value
Locked
Current Price
$2.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.